BIOMAT Database Logo BIOMAT Database Logo

[Therapy of psoriasis vulgaris with efalizumab]. 2006

Ulrich Mrowietz, and Joachim Barth, and Wolf-Henning Boehncke, and Kristian Reich, and Thomas Rosenbach, and Volker Streit, and Gottfried Wozel
Universitäts-Hauklinik Kiel. UMrowietz@dermatology.uni-kiel.de

UI MeSH Term Description Entries
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

Ulrich Mrowietz, and Joachim Barth, and Wolf-Henning Boehncke, and Kristian Reich, and Thomas Rosenbach, and Volker Streit, and Gottfried Wozel
Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris.
October 2005, The British journal of dermatology,
Ulrich Mrowietz, and Joachim Barth, and Wolf-Henning Boehncke, and Kristian Reich, and Thomas Rosenbach, and Volker Streit, and Gottfried Wozel
Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.
February 2007, BMC dermatology,
Ulrich Mrowietz, and Joachim Barth, and Wolf-Henning Boehncke, and Kristian Reich, and Thomas Rosenbach, and Volker Streit, and Gottfried Wozel
Efalizumab therapy in plaque psoriasis.
August 2004, Current rheumatology reports,
Ulrich Mrowietz, and Joachim Barth, and Wolf-Henning Boehncke, and Kristian Reich, and Thomas Rosenbach, and Volker Streit, and Gottfried Wozel
Exacerbation of psoriasis under efalizumab therapy.
January 2009, Journal of cutaneous medicine and surgery,
Ulrich Mrowietz, and Joachim Barth, and Wolf-Henning Boehncke, and Kristian Reich, and Thomas Rosenbach, and Volker Streit, and Gottfried Wozel
Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.
August 2005, BMC dermatology,
Ulrich Mrowietz, and Joachim Barth, and Wolf-Henning Boehncke, and Kristian Reich, and Thomas Rosenbach, and Volker Streit, and Gottfried Wozel
Immune thrombocytopenia associated with efalizumab therapy for psoriasis.
November 2005, Annals of internal medicine,
Ulrich Mrowietz, and Joachim Barth, and Wolf-Henning Boehncke, and Kristian Reich, and Thomas Rosenbach, and Volker Streit, and Gottfried Wozel
Efalizumab: continuous therapy for chronic psoriasis.
March 2005, Expert opinion on biological therapy,
Ulrich Mrowietz, and Joachim Barth, and Wolf-Henning Boehncke, and Kristian Reich, and Thomas Rosenbach, and Volker Streit, and Gottfried Wozel
Clinical considerations of efalizumab therapy in patients with psoriasis.
March 2005, Seminars in cutaneous medicine and surgery,
Ulrich Mrowietz, and Joachim Barth, and Wolf-Henning Boehncke, and Kristian Reich, and Thomas Rosenbach, and Volker Streit, and Gottfried Wozel
Successful treatment of hand and foot psoriasis with efalizumab therapy.
October 2006, Journal of drugs in dermatology : JDD,
Ulrich Mrowietz, and Joachim Barth, and Wolf-Henning Boehncke, and Kristian Reich, and Thomas Rosenbach, and Volker Streit, and Gottfried Wozel
Long-term management of plaque psoriasis with continuous efalizumab therapy.
April 2006, Journal of the American Academy of Dermatology,
Copied contents to your clipboard!